Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System
Related Experiment Video
Updated: Dec 14, 2025

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Sascha Röth1, Thomas J Macartney1, Agnieszka Konopacka2
1Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
Abstract:
K-RAS is known as the most frequently mutated oncogene. However, the development of conventional K-RAS inhibitors has been extremely challenging, with a mutation-specific inhibitor reaching clinical trials only recently. Targeted proteolysis has emerged as a new modality in drug discovery to tackle undruggable targets. Our laboratory has developed a system for targeted proteolysis using peptidic high-affinity binders, called "AdPROM." Here, we used CRISPR/Cas9 technology to knock in a GFP tag on the native K-RAS gene in A549 adenocarcinoma (A549GFPKRAS) cells and constructed AdPROMs containing high-affinity GFP or H/K-RAS binders. Expression of GFP-targeting AdPROM in A549GFPKRAS led to robust proteasomal degradation of endogenous GFP-K-RAS, while expression of anti-HRAS-targeting AdPROM in different cell lines resulted in the degradation of both GFP-tagged and untagged K-RAS, and untagged H-RAS. Our findings imply that endogenous RAS proteins can be targeted for proteolysis, supporting the idea of an alternative therapeutic approach to these undruggable targets.
Insights
Targeted proteolysis using AdPROMs effectively degrades oncogenic K-RAS proteins. This novel approach offers a promising therapeutic strategy for previously undruggable K-RAS mutations.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- K-RAS is a frequently mutated oncogene, posing challenges for conventional inhibitor development.
- Targeted proteolysis offers a new modality to address previously undruggable targets.
- AdPROM system utilizes peptidic binders for targeted protein degradation.
Purpose of the Study:
- To develop and evaluate AdPROMs for targeted proteolysis of endogenous RAS proteins.
- To assess the efficacy of GFP- and H/K-RAS-targeting AdPROMs in cancer cell lines.
Main Methods:
- CRISPR/Cas9 gene editing to knock in a GFP tag on the native K-RAS gene in A549 cells (A549GFPKRAS).
- Construction of AdPROMs with high-affinity GFP or H/K-RAS binders.
- Expression of AdPROMs in engineered and native cell lines to induce proteasomal degradation.
Main Results:
- GFP-targeting AdPROM induced robust proteasomal degradation of endogenous GFP-K-RAS in A549GFPKRAS cells.
- Anti-HRAS-targeting AdPROM degraded both GFP-tagged and untagged K-RAS, as well as untagged H-RAS, in various cell lines.
- Demonstrated successful targeted degradation of endogenous RAS proteins.
Conclusions:
- Endogenous RAS proteins can be effectively targeted for proteolysis using the AdPROM system.
- This approach provides a potential alternative therapeutic strategy for targeting undruggable RAS mutations.
- AdPROM-mediated targeted proteolysis shows promise for cancer therapy.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
In-vitro Mutagenesis

